Haemocomplettan® P During Aortic Replacement
2013年9月18日 更新者:CSL Behring
Haemocomplettan® P in Patients Experiencing Acute Bleeding While Undergoing Aortic Replacement Surgery
The primary purpose is to show that administration of Haemocomplettan® P significantly reduces the amount of blood products needed during aortic surgery.
研究概览
研究类型
介入性
注册 (实际的)
80
阶段
- 阶段2
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
-
Hannover、德国
- Medical School Hannover (MHH)
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Eighteen years of age or older
- Undergoing elective thoracoabdominal aortic replacement surgery (TAAA) or thoracic aortic replacement surgery (TAA)
- Understood and willingly given written informed consent (German language) to participate following an explanation of study background, restrictions, and procedures
- Experience clinically relevant bleeding of the microvasculature following removal of CPB during surgery
Exclusion Criteria:
- Positive pregnancy test, pregnancy or lactation
- Women of child bearing age not using a medically approved method of contraception during the study
- Previous aortic replacement at the same aortic site (redo surgeries)
- Undergoing an emergency operation
- Proof or suspicion of a congenital or acquired coagulation disorder (e.g. VWD or via severe liver disease)
- Myocardial Infarction (MI) or apoplexy in the 2 months preceding study surgery
- ASA administration in the 3 days preceding study surgery, and a pathological (<74.5 U) ASPI Multiplate® test immediately preceding surgery begin
- Clopidogrel administration in the 5 days preceding study surgery, and a pathological (<31.1 U) ADP/PG Multiplate® test immediately preceding surgery begin
- Tirofiban administration in the 2 days preceding study surgery, and a pathological (<94.1 U) TRAP Multiplate® test immediately preceding surgery begin
- Phenprocoumon administration in the 5 days preceding study surgery, and an INR > 1.28 immediately preceding surgery begin
- Participation in another clinical study in the 4 weeks preceding aortic replacement
- Sensitivity to any of the components of study medication, or to MPs with a similar chemical structure to any of the components of study medication
- Any indication that the restrictions or procedures of the study may not be adhered to (e.g. an uncooperative attitude)
- Any indication that the study restrictions, procedures, or consequences therein have not been considered or understood, such that informed consent cannot be convincingly given
- Multiple morbidities, with a notably constrained remaining length of life
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:生理盐水
|
Single intravenous infusion
|
|
有源比较器:Haemocomplettan® P
Intravenous infusion during aortic surgery
|
Single intravenous infusion
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Combined number of units of allogeneic blood products (platelets + FFP + RBCs) administered to subjects.
大体时间:From administration of Haemocomplettan® P until 24 hours later
|
From administration of Haemocomplettan® P until 24 hours later
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Proportion of subjects that receive no allogeneic blood products (neither platelets, FFP, nor RBCs)
大体时间:From administration of Haemocomplettan® P until 24 hours later
|
From administration of Haemocomplettan® P until 24 hours later
|
|
Duration of stay in ICU
大体时间:Last suture of initial surgery to end of ICU stay
|
Last suture of initial surgery to end of ICU stay
|
|
Duration of hospital stay
大体时间:Last suture of initial surgery to end of hospital stay
|
Last suture of initial surgery to end of hospital stay
|
|
Mortality
大体时间:45 days post surgery
|
45 days post surgery
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
赞助
调查人员
- 首席研究员:Niels Rahe-Meyer, Dr. Dr.、Abteilung Anästhesiologie, Carl-Neuberg-Strasse 1 / K5, 30177 Hannover
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- Rahe-Meyer N, Solomon C, Hanke A, Schmidt DS, Knoerzer D, Hochleitner G, Sorensen B, Hagl C, Pichlmaier M. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial. Anesthesiology. 2013 Jan;118(1):40-50. doi: 10.1097/ALN.0b013e3182715d4d. Erratum In: Anesthesiology. 2013 May;118(5):1244.
- Rahe-Meyer N, Hanke A, Schmidt DS, Hagl C, Pichlmaier M. Fibrinogen concentrate reduces intraoperative bleeding when used as first-line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo-controlled trial. J Thorac Cardiovasc Surg. 2013 Mar;145(3 Suppl):S178-85. doi: 10.1016/j.jtcvs.2012.12.083.
- Schochl H, Posch A, Hanke A, Voelckel W, Solomon C. High-dose fibrinogen concentrate for haemostatic therapy of a major trauma patient with recent clopidogrel and aspirin intake. Scand J Clin Lab Invest. 2010 Oct;70(6):453-7. doi: 10.3109/00365513.2010.500396.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2008年6月1日
初级完成 (实际的)
2010年3月1日
研究完成 (实际的)
2010年4月1日
研究注册日期
首次提交
2008年6月16日
首先提交符合 QC 标准的
2008年6月18日
首次发布 (估计)
2008年6月19日
研究记录更新
最后更新发布 (估计)
2013年9月20日
上次提交的符合 QC 标准的更新
2013年9月18日
最后验证
2011年2月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.